he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源郵箱
下一頁:隱源性癲癇死亡率少于
- 2022-05-04孕期腦積水 媽媽怎么做才能預防孕期腦積水
- 2022-04-262013年的國際抗癲癇聯合會抗癲癇藥使用指南
- 2022-04-21癲癇病誘發的主要病變是什么
- 癲癇治愈費用
- 2013國際抗癲癇聯合會抗癲癇藥用指南
- 癲癇患者停藥問題解決了嗎?最新的預測模型已經發布!
- 月經性癲癇患者妊娠期癲癇控制更好
- 抗癲癇藥物預防新發癲癇:任重而道遠
- FDA批準開浦蘭治療1個月至4歲癲癇兒童
- 北京癲癇醫院治療費用
- 【用藥問答】癲癇發作和局限性發作的首選治療是什么?
- 第四屆全國臨床腦電圖實踐基礎理論與實踐操作培訓班
- 常見的癲癇病因有哪些?
- NeuroImage:纖維球成像可用于癲癇的進展
- 油炸刀魚 酥脆的美味食物
- 癲癇猝死:兇手是誰?
- 2015 神經系統疾病診療進展
- UCB的Vimpat癲癇新適應癥在美國獲批
- 三庚酸酯可治療1型轉運體缺陷綜合征
- 癲癇患者手術評估新型工具
- 手術學習:顱內脊索瘤內鏡下三腦室入路治療
- PLoS ONE:新的合成蛋白能快速激活免疫系統抵抗流感
- 北京哪家癲癇醫院排名好,成本低
- 英國競爭監管機構指控輝瑞癲癇藥品價格過高
- FDA批準Aptiom用于治療患者癲癇發作
- 癲癇發作的癥狀是什么?
- 綜述:癲癇持續狀態診治最新進展
- 預測癲癇患者再入院風險
- 38癲癇患者年病史上的感謝信 道出了濃濃的醫患情況
- 癲癇治療障礙仍難以克服
- 財政部:新型大腸桿菌感染肺炎患者個人負擔費用實行財政兜底
- 油煎龍蝦 香酥的美味食品
- 大咖直播—6 大公益援助編撰:國際癲癇關愛日,患者最高可獲 10 萬元手術費用減免
- Neurology:功能影像呈現神經句法網絡可塑性證據,癲癇兒童存在靜息狀態功能連接性(FC)差異
- 消化不良病的治療方法是什么 消化不良病有這些偏方
- 太原癲癇病醫院:癲癇患者冬季易導致中風頻繁發作
- 首次癇性發作該如何處理?這 3 個問題需厘清
- 發生率學習:典型拉福拉病一例
- 上海率先探索時才就醫門診費用直接結算
- 馬鈴薯配伍排骨 補腎又養胃
- 癲癇患者日常應該如何烹飪
- 肺源性心臟病可能并發左心功能不全嗎?如何擬定治療方案?
- 20130712氣功:楊紅宣講癲癇病人不能吃什么